Kodak, InSiteOne, and Cedara have agreed to ally with Fischer Imaging to expand the mammography company's offerings in image networking and display. Kodak will provide its Versatile Intelligent Patient Archive (VIParchive) management software in
Kodak, InSiteOne, and Cedara have agreed to ally with Fischer Imaging to expand the mammography company's offerings in image networking and display. Kodak will provide its Versatile Intelligent Patient Archive (VIParchive) management software in combination with Fischer's Senoscan digital mammography system. Kodak has incorporated the VIParchive software within its DirectView PACS System 5 as an enterprise-wide management solution. InSiteOne will offer Fischer customers "pay-as-you-go, price per study" services that include online, nearline, and disaster recovery/business continuance image storage and access. Cedara Software will work with Fischer in the sale, marketing, and support of its I-ReadMammo dedicated mammography workstation customized for Cedara with Senoscan.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.